Although active cancer is recognised as a risk factor for increased bleeding, the specific bleeding risks associated with ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

A UK-led international clinical trial is recruiting 280 patients to see if the technique to remove cancerous cells could ...

The APP ordered a bilateral diagnostic mammogram and left breast ultrasound that revealed extremely dense breast tissue, a ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

Instead, he chose to be the first person in Texas to try Inlexzo. Inlexzo is a chemotherapy that comes in a tube that looks ...

The results to be presented by Prof Emmett at the EAU Congress 2026 will expand on the earlier findings that the trial met its primary endpoint, demonstrating that 64 Cu-SAR-bisPSMA positron emission ...

A published case series reports unexpected cancer remissions linked with fenbendazole use, prompting renewed discussion on ...

The MCED test shows similar performance in cancer survivors and the general population, with a PPV of 50% and high ...

PYLCLARI® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec. 23, ...

Treatments for localised prostate cancer have long been aimed at treating the whole prostate, either by surgical removal or by radiotherapy. However ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...